Capital International Sarl Trims Bristol Myers Squibb Holdings

Hedge fund reduces stake in biopharmaceutical company by over 25% in Q3

Mar. 11, 2026 at 8:33am

Got story updates? Submit your updates here. ›

Capital International Sarl, a major investment firm, trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 26.5% during the third quarter of 2025, according to a recent 13F filing with the SEC. The fund now owns 118,926 shares of the biopharmaceutical company's stock, valued at $5,364,000 at the end of the reporting period.

Why it matters

Bristol Myers Squibb is a leading global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases. Changes in major institutional holdings can signal shifts in investor sentiment and provide insights into the company's performance and outlook.

The details

According to the 13F filing, Capital International Sarl sold 42,797 shares of Bristol Myers Squibb during the third quarter, reducing its total position by 26.5%. The hedge fund's remaining stake in the company is now valued at $5,364,000. Bristol Myers Squibb's stock price has seen significant volatility in recent quarters, with the company reporting mixed financial results and facing competitive pressures in some of its key therapeutic areas.

  • Capital International Sarl filed its 13F report for the third quarter of 2025.

The players

Capital International Sarl

A major global investment management firm that has been an institutional investor in Bristol Myers Squibb.

Bristol Myers Squibb Company

A leading biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital International Sarl's Bristol Myers Squibb holdings suggests potential concerns about the company's near-term outlook, though the stock remains a holding in the hedge fund's portfolio. Investors will be closely watching Bristol Myers Squibb's future financial performance and strategic moves as it navigates a competitive biopharmaceutical landscape.